ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
30.04
-0.29 (-0.96%)
At close: Apr 28, 2026, 4:00 PM EDT
30.15
+0.11 (0.37%)
After-hours: Apr 28, 2026, 7:44 PM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 42.18, with a low estimate of 32 and a high estimate of 50. The average target predicts an increase of 40.41% from the current stock price of 30.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 10 | 10 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $33 → $45 | Strong Buy | Maintains | $33 → $45 | +49.80% | Apr 24, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $37 → $45 | Strong Buy | Maintains | $37 → $45 | +49.80% | Mar 23, 2026 |
| BTIG | BTIG | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +39.81% | Mar 12, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $44 → $50 | Buy | Reiterates | $44 → $50 | +66.44% | Mar 6, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +9.85% | Mar 6, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
47.09M
EPS This Year
-3.83
from -4.32
EPS Next Year
-3.31
from -3.83
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 84.4M | ||||||
| Avg | n/a | 47.1M | ||||||
| Low | n/a | 20.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.20 | -2.45 | ||||||
| Avg | -3.83 | -3.31 | ||||||
| Low | -4.60 | -4.86 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.